The investigators of PRECISE-DAPT devised a five-item score to predict out-of-hospital bleeding risk in patients treated with dual antiplatelet therapy (DAPT) after coronary stenting. In patients at high risk of bleeding treated with prolonged DAPT, significantly more bleeding events were observed, with no reduction in ischaemic events.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bittl, J. A., Baber, U., Bradley, S. M. & Wijeysundera, D. N. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J. Am. Coll. Cardiol. 68, 1116–1139 (2016).
Généreux, P. et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J. Am. Coll. Cardiol. 66, 1036–1045 (2015).
Costa, F. et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 389, 1025–1034 (2017).
Schulz-Schupke, S. et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 versus 12 months of clopidogrel therapy after drug-eluting stenting. Eur. Heart J. 36, 1252–1263 (2015).
Mauri, L. et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N. Engl. J. Med. 371, 2155–2166 (2014).
Palmerini, T. et al. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur. Heart J. 38, 1034–1043 (2017).
Yeh, R. W. et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 315, 1735–1749 (2016).
Baber, U. et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. J. Am. Coll. Cardiol. 67, 2224–2234 (2016).
Bonaca, M. P. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med. 372, 1791–1800 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.M.B. has received advisory/consulting/speakers fees from Accumetrics, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, the Medicines Company, and Pfizer, and has received research grants from AstraZeneca and ZonMw. B.Z. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Zwart, B., ten Berg, J. New score for predicting bleeding risk after DAPT. Nat Rev Cardiol 14, 321–322 (2017). https://doi.org/10.1038/nrcardio.2017.71
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2017.71
